JP2025503322A5 - - Google Patents
Info
- Publication number
- JP2025503322A5 JP2025503322A5 JP2024565245A JP2024565245A JP2025503322A5 JP 2025503322 A5 JP2025503322 A5 JP 2025503322A5 JP 2024565245 A JP2024565245 A JP 2024565245A JP 2024565245 A JP2024565245 A JP 2024565245A JP 2025503322 A5 JP2025503322 A5 JP 2025503322A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- pharmaceutically acceptable
- sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210089838 | 2022-01-25 | ||
| CN202210089838.7 | 2022-01-25 | ||
| PCT/CN2023/072657 WO2023143263A1 (zh) | 2022-01-25 | 2023-01-17 | 一种针对Her3的抗体,偶联物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503322A JP2025503322A (ja) | 2025-01-30 |
| JP2025503322A5 true JP2025503322A5 (cg-RX-API-DMAC7.html) | 2026-01-26 |
Family
ID=87470655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024565245A Pending JP2025503322A (ja) | 2022-01-25 | 2023-01-17 | Her3に対する抗体、複合体、及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4471063A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025503322A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240137076A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118891283A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023210897A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3243294A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL314470A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024009174A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202334206A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023143263A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202406384B (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4623936A1 (en) * | 2022-11-22 | 2025-10-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Fused ring compound, conjugate thereof and use thereof |
| EP4688787A1 (en) * | 2023-04-07 | 2026-02-11 | Innovent Biologics (Suzhou) Co., Ltd. | Antibody-drug conjugates of camptothecin derivatives and uses thereof |
| EP4692091A1 (en) * | 2023-04-07 | 2026-02-11 | Changchun Genescience Pharmaceutical Co., Ltd. | Camptothecin derivative, and pharmaceutical composition, preparation method therefor and use thereof |
| JPWO2024248123A1 (cg-RX-API-DMAC7.html) | 2023-06-02 | 2024-12-05 | ||
| CN122121899A (zh) * | 2023-08-18 | 2026-05-29 | 康诺亚生物医药科技有限公司 | 五环类活性化合物及其偶联物和用途 |
| AU2024380559A1 (en) | 2023-11-17 | 2026-06-04 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| TW202539743A (zh) * | 2024-02-07 | 2025-10-16 | 大陸商長春金賽藥業有限責任公司 | 帶有連接系統的抗體藥物偶聯物 |
| TW202547557A (zh) * | 2024-05-30 | 2025-12-16 | 德商拜恩技術股份公司 | 抗體藥物結合物之新用途 |
| WO2026086850A1 (en) * | 2024-10-23 | 2026-04-30 | Zai Lab (Shanghai) Co., Ltd. | Dosing regimens of antibody-drug conjugate targeting delta-like ligand 3 for treatment of neuroendocrine neoplasms |
| WO2026151884A1 (en) | 2025-01-09 | 2026-07-16 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| WO2026153342A1 (zh) * | 2025-01-16 | 2026-07-23 | 北京泰德制药股份有限公司 | Her3结合蛋白及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| CA2813796C (en) | 2010-10-18 | 2019-01-15 | Mediapharma S.R.L. | Erbb3 binding antibody |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| TWI871999B (zh) * | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| CN105367657B (zh) * | 2014-08-14 | 2019-09-13 | 上海生物制品研究所有限责任公司 | 抗her3抗体、其制法及其应用 |
| EP3091033A1 (en) * | 2015-05-06 | 2016-11-09 | Gamamabs Pharma | Anti-human-her3 antibodies and uses thereof |
| US12667557B2 (en) * | 2017-02-28 | 2026-06-30 | Daiichi Sankyo Company, Limited | Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate |
| CN111936169A (zh) | 2018-04-06 | 2020-11-13 | 西雅图遗传学公司 | 喜树碱肽缀合物 |
| WO2019241893A2 (en) * | 2018-06-22 | 2019-12-26 | Crd Pharmaceuticals Inc | Anti-her3 antibody and uses thereof |
| CN113135995B (zh) * | 2020-01-17 | 2022-08-12 | 上海生物制品研究所有限责任公司 | 抗her3单克隆抗体及其应用 |
| CN120093941A (zh) * | 2021-02-09 | 2025-06-06 | 苏州宜联生物医药有限公司 | 生物活性物偶联物及其制备方法和用途 |
-
2023
- 2023-01-17 KR KR1020247028454A patent/KR20240137076A/ko active Pending
- 2023-01-17 MX MX2024009174A patent/MX2024009174A/es unknown
- 2023-01-17 CN CN202380018294.8A patent/CN118891283A/zh active Pending
- 2023-01-17 WO PCT/CN2023/072657 patent/WO2023143263A1/zh not_active Ceased
- 2023-01-17 JP JP2024565245A patent/JP2025503322A/ja active Pending
- 2023-01-17 AU AU2023210897A patent/AU2023210897A1/en active Pending
- 2023-01-17 CA CA3243294A patent/CA3243294A1/en active Pending
- 2023-01-17 EP EP23746145.4A patent/EP4471063A4/en active Pending
- 2023-01-17 IL IL314470A patent/IL314470A/en unknown
- 2023-01-17 TW TW112102062A patent/TW202334206A/zh unknown
-
2024
- 2024-08-20 ZA ZA2024/06384A patent/ZA202406384B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7118117B2 (ja) | 抗体-薬物コンジュゲートの選択的製造方法 | |
| JP2024508081A5 (cg-RX-API-DMAC7.html) | ||
| CN112543771B (zh) | 抗b7h3抗体-依喜替康类似物偶联物及其医药用途 | |
| TWI888610B (zh) | 抗cd79b抗體藥物偶聯物、其製備方法及其醫藥用途 | |
| JP2022515318A5 (cg-RX-API-DMAC7.html) | ||
| CN104341504B (zh) | 双特异性抗体 | |
| JP2024544520A5 (cg-RX-API-DMAC7.html) | ||
| JP6914956B2 (ja) | 抗5t4抗体および抗体−薬物コンジュゲート | |
| CA3199566A1 (en) | Anti-cd276 antibody, antibody-drug conjugate, and use thereof | |
| CN116999573A (zh) | 抗体-药物偶联物及其制造方法、药物组合物及其在制备治疗肿瘤的药物中的应用 | |
| JP7827624B2 (ja) | 抗cea抗体-エキサテカン類似体複合体及びその医薬用途 | |
| RU2014113304A (ru) | Анти-cd40-антитела, применение и методы | |
| EP3442574A1 (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof | |
| JP2016518382A (ja) | Axl抗体薬物複合体および癌の治療のためのその使用 | |
| TW202537975A (zh) | 抗體-藥物結合物之製造方法 | |
| JP2025508009A5 (cg-RX-API-DMAC7.html) | ||
| JP2014531201A5 (cg-RX-API-DMAC7.html) | ||
| CN116948035A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2022506761A5 (cg-RX-API-DMAC7.html) | ||
| EP4374879A1 (en) | Drug conjugate of eribulin derivative | |
| AU2024340685A1 (en) | Her3/met binding molecule and pharmaceutical use thereof | |
| WO2024230678A1 (zh) | 喜树碱类化合物及其偶联物、其制备方法和用途 | |
| JP2024508597A5 (cg-RX-API-DMAC7.html) | ||
| JP2025511002A5 (cg-RX-API-DMAC7.html) | ||
| WO2025056748A1 (en) | Antibody-drug conjugate |